1001180-04-6

Basic information

• Product Name: Boc-(S)-3-aMino-2-(4-chlorophenyl)propanoic acid
• Synonyms: Boc-(S)-3-aMino-2-(4-chlorophenyl)propanoic acid;(S)-3-tert-Butoxycarbonylamino-2-(4-chloro-phenyl)-propionic acid;(S)-3-((TERT-BUTOXYCARBONYL)AMINO)-2-(4-CHLOROPHENYL)PROPANOIC ACID
• CAS NO: 1001180-04-6
• Molecular Formula: C₁₄H₁₈ClNO₄
• Molecular Weight: 299.75002
• EINECS: -0
• Mol File: 1001180-04-6.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: Boc-(S)-3-aMino-2-(4-chlorophenyl)propanoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: Boc-(S)-3-aMino-2-(4-chlorophenyl)propanoic acid(1001180-04-6)
• EPA Substance Registry System: Boc-(S)-3-aMino-2-(4-chlorophenyl)propanoic acid(1001180-04-6)

Safety Data

• Hazardous Substances Data: 1001180-04-6(Hazardous Substances Data)

Upstream product

• 1001179-98-1 tert-butyl 2,4-dimethoxybenzyl((S)-3-((R)-4-benzyl-2-oxooxazolidin-3-yl)-2-(4-chlorophenyl)-3-oxopropyl)carbamate 
• 1001179-95-8 tert-butyl 2,4-dimethoxybenzyl(methoxymethyl)carbamate 
• 1001181-01-6 tert-butyl 2,4-dimethoxybenzylcarbamate 
• 1001180-07-9 (S)-3-amino-2-(4-chlorophenyl)propanoic acid hydrochloride 
• 24424-99-5 di-tert-butyl dicarbonate 
• 1001180-01-3 tert-butyl (S)-(3-((R)-4-benzyl-2-oxooxazolidin-3-yl)-2-(4-chlorophenyl)-3-oxopropyl)carbamate 

Downstream Products

• 1001180-07-9 (S)-3-amino-2-(4-chlorophenyl)propanoic acid hydrochloride 

Relevant articles and documents

COMBINATIONS OF AKT INHIBITOR COMPOUNDS AND VEMURAFENIB, AND METHODS OF USE

The invention provides a combination of a) a compound of Formula Ia: [insert Formula Ia], or a pharmaceutically acceptable salt thereof, and b) vemurafenib or a pharmaceutically acceptable salt thereof for the prophylactic or therapeutic treatment of a hy

HYDROXYLATED AND METHOXYLATED CYCLOPENTA [D] PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS

The present invention provides compounds, including resolved enantiomers, resolved diastereomers, solvates and pharmaceutically acceptable salts thereof, comprising the Formula (I). Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.